WESTMINSTER, Colo., June 19 (UPI) -- U.S. firm Allos Therapeutics said Tuesday it has disappointing data from a study of efaproxyn in women with breast cancer-originating brain cancer.
The company said it would discontinue developing the drug, based on results from its phase 3, ENRICH study of efaproxyn in combination with whole brain radiation, where the drug failed to achieve its primary endpoint of statistically significant improvement in overall survival in patients who have brain metastases that originated from breast cancer.
Allos said it would turn its attention to pralatrexate (PDX), the drug it is developing for relapsed or refractory peripheral T-cell lymphoma.
"Although we are disappointed with the results of the ENRICH study, we are excited about the potential of our product pipeline," said Pablo Cagnoni, Allos' chief medical officer. "We expect to provide the next update on our PDX PROPEL study later this year following completion of a pre-specified interim analysis of response data after 35 patients have completed at least one cycle of treatment with PDX."